Zobrazeno 1 - 10
of 319
pro vyhledávání: '"M Mokan"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Thrombosis and Thrombolysis. 49:578-583
Edoxaban is an oral anticoagulant drug and a direct factor Xa inhibitor. However, it is still not fully understood if and how edoxaban impacts platelet function. This prospective study aimed to assess in vitro platelet function in patients with atria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f49cf3583ecb40493611b6d7add8875f
https://doi.org/10.1007/s11239-020-02093-9
https://doi.org/10.1007/s11239-020-02093-9
Publikováno v:
American Journal of Therapeutics. 27:e159-e164
Background Many patients receiving dabigatran treatment might also require bisoprolol therapy. However, there is a possibility that bisoprolol as significant P-glycoprotein inhibitor might interact with dabigatran. Study question To investigate the i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b37b5691ba7b579d32797fb14935c828
https://doi.org/10.1097/mjt.0000000000000786
https://doi.org/10.1097/mjt.0000000000000786
Publikováno v:
Bratislavske lekarske listy. 122(11)
OBJECTIVES The objective was to find out risk factors indicating the patients directly to selective coronarography (SCG) to avoid unnecessary non-invasive testing and in their absence to asses low cardiovascular risk and faster inclusion on the waiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af73a52e430e6b37c3e047dbd145422d
https://pubmed.ncbi.nlm.nih.gov/34672667
https://pubmed.ncbi.nlm.nih.gov/34672667
Publikováno v:
American Journal of Therapeutics. 26:e649-e652
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3f6a79c5d0a22abaa35eb30550e5699
https://doi.org/10.1097/mjt.0000000000000851
https://doi.org/10.1097/mjt.0000000000000851
Autor:
Ivana Dedinská, Matej Vnučák, K. Granak, Petra Skálová, Bena L, Zuzana Zilinska, Laca L, Lea Kováčiková, M. Mokan, E Lackova
Publikováno v:
Acta Medica Martiniana, Vol 18, Iss 3, Pp 24-29 (2018)
Background: Chronic kidney disease represents a world-wide health problem affecting approximately 195 million women around the world. Risk of development of chronic kidney disease is greater in women; therefore, the World Kidney Day 2018 was dedicate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc1d6918fa3b9f25008f9e075e861735
https://doi.org/10.2478/acm-2018-0014
https://doi.org/10.2478/acm-2018-0014
Autor:
Jana Zolkova, Juraj Sokol, Frantisek Nehaj, Jela Ivankova, Marian Mokan, Jan Stasko, Ludmila Linekova, M. Mokan, Lenka Lisa
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 27 (2021)
Clinical and Applied Thrombosis/Hemostasis
Clinical and Applied Thrombosis/Hemostasis
A rapid and reliable assessment of the dabigatran effect is desirable in dabigatran treated patients with uncontrolled bleeding or before acute surgery. The aim of this study was to study the anticoagulant effects of dabigatran in patients with atria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4281b5602863a96ec87eff35d9528c41
https://doaj.org/article/45ffc6ca78f2438e8496473c24f36106
https://doaj.org/article/45ffc6ca78f2438e8496473c24f36106
Publikováno v:
Medicine
Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, life-threatening hemopoietic stem cell disorder characterized by the triad of hemolytic anemia, thrombosis, and impaired bone marrow function. Evidence suggests that severe outco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8f79c405b7e7ef06648344c229fd0da
https://pubmed.ncbi.nlm.nih.gov/34011023
https://pubmed.ncbi.nlm.nih.gov/34011023
Autor:
Jela Ivankova, Jan Stasko, Frantisek Nehaj, Lenka Lisa, Marian Mokan, L Vadelova, Juraj Sokol, M. Mokan, Jana Zolkova
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
Clinical and Applied Thrombosis/Hemostasis
Clinical and Applied Thrombosis/Hemostasis
Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use. As the main adverse event is bleeding, it is relevant whether edoxaban has additional effects on platelet function. We aimed to as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7eb448c6739645d170557342e759a060
https://doaj.org/article/90ee2f85093240908bd3f4c5594d9b6e
https://doaj.org/article/90ee2f85093240908bd3f4c5594d9b6e